Should Psychedelic Therapists Have Personal Experience?

If a treatment could profoundly change how you experience your thoughts, emotions, and surroundings, would you want the person guiding you to have experienced something similar? For psychedelic therapy, that question sits at the intersection of patient trust, professional training, and scientific evidence.

A new study accepted for publication in Psychedelics examines how participants in a psilocybin clinical trial viewed therapists’ and researchers’ personal psychedelic experience.¹ Participants moderately valued that experience, while reporting relatively low concern that it would introduce research bias.

However, the findings do not establish that taking psychedelics makes someone a better therapist. Their significance is more practical: they reveal a patient preference that training programs and clinical teams should understand without confusing it with proof of competence.

What The Psilocybin Study Examined

The research drew on a University of Utah trial involving 25 physicians and nurses experiencing depression and burnout related to frontline work during the COVID-19 pandemic. Participants were randomly assigned to eight weeks of mindfulness-based stress reduction, either alone or combined with group psilocybin-assisted psychotherapy.

The psilocybin group received a 25-milligram dose, with one therapist per participant during group administration. Three preparatory sessions preceded dosing, and three integration sessions followed it. Integration refers to helping participants reflect on an experience and connect it with everyday life.

The original randomized trial reported clinical outcomes separately in 2025. This new paper focuses on attitudes toward personal psychedelic experience, rather than offering a new test of psilocybin’s effectiveness.

Two weeks after completing their assigned intervention, 19 participants answered three questions. These asked how important or desirable prior psilocybin experience seemed for therapists and study teams, and how much participants thought study team experience introduced bias.

Participants Valued Firsthand Psychedelic Experience

Across respondents, therapist experience received an average importance rating of 6.6 out of 10. Study team experience received 7.1, while perceived bias averaged 3.1. On these scales, five represented a neutral response.

Respondents in the psilocybin arm rated therapist experience somewhat higher than those receiving mindfulness alone. However, between-group differences were not statistically significant, and uncertainty around the estimates was substantial.

Participants with their own prior psychedelic experience also gave somewhat higher ratings. These differences were not statistically significant either. The appropriate conclusion is that the sample showed a moderate preference, while providing limited evidence about what shaped it.

Patient Trust Is Different From Therapist Competence

The appeal of firsthand experience is understandable. Someone preparing for an unfamiliar altered state may want reassurance that a guide understands its emotional intensity. That preference could reflect a desire to feel understood, rather than a belief that drug use itself constitutes a professional qualification.

Consider a patient who fears losing control during treatment. Knowing a therapist has encountered an altered state might feel reassuring. Yet the skills that matter during a difficult session include recognizing distress, communicating calmly, respecting boundaries, and knowing when medical assistance is needed.

Personal experience could potentially inform those skills, but it cannot demonstrate them. A therapist’s own experience could also differ substantially from a patient’s, creating a risk of assuming that the same interpretation or response fits everyone.

This suggests a useful distinction for future care: experiential credibility may help someone feel comfortable, while clinical competence must be demonstrated through observable practice. Good training should investigate whether the former improves the latter, rather than treating them as interchangeable.

Why Personal Disclosure Needs Care

The study team did not disclose personal psychedelic histories to participants. Staff used a scripted response acknowledging the question while explaining that they could not discuss personal use within the trial.

That detail matters. The findings describe what participants wanted, rather than how confirmed knowledge of a therapist’s history affected trust or treatment. They also do not establish that therapists should disclose such histories.

A disclosure policy should serve the patient. If a therapist’s story creates expectations about a dramatic revelation or a particular spiritual meaning, it could narrow the patient’s freedom to interpret their own experience. Reassurance should leave room for individual differences.

Better Psychedelic Training Can Focus On Demonstrable Skills

The productive next step is to translate the qualities patients may associate with firsthand experience into skills that training can evaluate. If the desired quality is empathy during an unfamiliar state, programs can assess how trainees respond to uncertainty and distress.

Potential approaches include supervised practice, role-playing difficult situations, structured feedback, and reflection on personal assumptions. These are proposals for developing competence, not alternatives proven by this study to reproduce the effects of psychedelic experience.

• Recognize distress without imposing a personal interpretation.
• Communicate clearly about consent, boundaries, and uncertainty.
• Support integration without promising a particular outcome.

This approach also offers an equity advantage. Requiring clinicians to take psychedelics could exclude people for medical, legal, religious, or cultural reasons. The paper explicitly identifies these concerns. A profession benefits from asking what practitioners can demonstrate, while carefully studying which training experiences improve care.

Research Integrity And Patient Confidence Can Coexist

Therapists and researchers have overlapping but distinct responsibilities. A therapist supports an individual through treatment. A research team must also produce evidence that remains credible whether a therapy works impressively, modestly, or not at all.

A 2025 survey of psychedelic researchers found that 85% of 111 respondents reported experience with classic psychedelics. Respondents generally viewed personal experience as beneficial to research, while also recognizing it as a possible source of bias.

That combination supports a constructive response: enthusiasm can motivate research, while independent scrutiny helps test its conclusions. In the Utah trial, at least one member of the data safety and monitoring board had no personal psychedelic experience.

Participants’ low concern about bias should not be treated as evidence that bias was absent. Perceived credibility and methodological reliability are different questions. Strong research needs safeguards even when patients feel confident in the people conducting it.

What Cannabis Readers Can Learn From The Debate

For cannabis readers, the broader lesson concerns how emerging treatments earn legitimacy. Familiarity with a substance may support conversation, but therapeutic claims still require evidence, and professional practice requires standards.

MyCannabis’s coverage of medical cannabis lessons for psilocybin access explores how an established regulatory history might inform a newer field. Therapist training belongs within that discussion: access becomes more meaningful when patients can understand what qualifications and safeguards actually represent.

However, common policy questions do not make these treatments interchangeable. Research discussed in how psilocybin and cannabis affect the brain differently reinforces the importance of examining each substance on its own terms. This study provides no evidence about cannabis-assisted treatment or CBD.

A Promising Question For The Next Phase Of Psychedelic Care

The study’s limitations are substantial. Only 19 people answered the questionnaire, the enrolled population was 96% white, and all participants were healthcare professionals. The three-question measure was unvalidated, and responses were collected after treatment, when rapport and group experiences could influence views.

Most importantly, researchers did not measure therapists’ actual psychedelic histories or test whether those histories predicted better outcomes. Larger studies should examine patient satisfaction, therapeutic relationships, safety, and clinical results alongside different forms of training.

The optimistic implication is that patients’ preferences can help identify what care should address. By studying the qualities behind the desire for firsthand experience, psychedelic medicine can develop training that earns trust through understanding, accountable practice, and evidence.

References:

¹ Lewis, B., Garland, E., Schwartz, Z., Xin, Y., Byrne, K., & Kious, B. (2026). Study participant perceptions of the relevance of therapist and study team personal psychedelic experience. Psychedelics, Article 100041. Advance online publication. https://doi.org/10.1016/j.psyche.2026.100041